EU5 Conjugate Vaccine Market (2018-2023)

June 2018 | 75 pages | ID: E752DEEAEB3EN
Netscribes (India) Pvt. Ltd.

Abstracts

The report is sent in 5-10 business days after order is placed.

EU5 Conjugate Vaccine Market:

Conjugate Vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. EU5 is one of the most prominent markets for conjugate vaccines.

The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained.

Market Segmentation:

• Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics is that of the DTP vaccine.
• Based on end user, the market is segmented into pediatric and adult.

Key growth factors:

The EU5 is projected to have positive growth during the forecasted period. A higher number of vaccination programs by the governments, increase in geriatric population, government initiatives and increase in research and development activities together propel the growth of this market. Germany will grow at a considerable rate over the coming years owing to increasing government initiatives which offer medical advice for the vaccination of children. Rising prevalence of infectious diseases and focused product development will fuel industry expansion.

Threats and key players:

• The EU5 conjugate vaccine market is expected to grow at a constant pace. Vaccine shortages, low access and stringent regulations are some of the challenges faced by this market which need to be addressed to achieve smooth growth.
• Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

What’s covered in the report?

1. Overview of the EU5 conjugate vaccine market
2. Market drivers and challenges in the EU5 conjugate vaccine market
3. Market trends in the EU5 conjugate vaccine market
4. Historical, current and forecasted market size data for EU5 based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for EU5 based on end user (pediatric and adult conjugate vaccines) – by revenue and by volume
6. Analysis of the competitive landscape and profiles of major companies operating in the EU5 market

Why buy?

• Understand the demand for conjugate vaccines to determine the viability of the market
• Develop strategies based on the drivers and trends for each of the segments
• Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
• Recognize the key competitors of this market and respond accordingly
• Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
• Define the competitive positioning by comparing the products and services with the key players in the market

Customizations available
With the given market data, Netscribes offers customizations according to specific needs.

Contents

CHAPTER 1: EXECUTIVE SUMMARY

1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary  I
1.4 Executive summary  II

CHAPTER 2: MARKET OVERVIEW

2.1. Market definitions
2.2. EU5 market overview – by revenue
  EU5 historical (2015-2017) market revenue (USD Bn)
  EU5 forecasted (2018-2023) market revenue (USD Bn)
2.3. EU5 market overview – by volume
  EU5 historical (2015-2017) market volume (Million units)
  EU5 forecasted (2018-2023) market volume (Million units)
2.4. EU5 market drivers and challenges
  2.4.1. EU5 market drivers
  2.4.2. EU5 market challenges
2.5. EU5 market trends
2.6. Value chain

CHAPTER 3: EU5 MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION

3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): Pneumococcal – EU5 (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Hib – EU5 (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
  Overview by disease indication
  Market share (2015, 2018 & 2023): DTP – EU5 (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Meningococcal – EU5 (USD Bn, Million units)

CHAPTER 4: EU5 MAJOR SEGMENT OVERVIEW BY END USER

4.1. End user: Pediatric, Adult by revenue, by volume, CAGR
  Overview by end user
  Market share (2015, 2018 & 2023): Paediatric – EU5 (USD Bn, Million units)
  Market share (2015, 2018 & 2023): Adult – EU5 (USD Bn, Million units)

CHAPTER 5: COMPETITIVE LANDSCAPE

5.1. Company market share
  Top 5 companies
5.2. Company overview GlaxoSmithKline
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.2(A) Executive profile – GlaxoSmithKline
5.3. Company overview – Pfizer Inc.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.3(A) Executive profile  Pfizer Inc.
5.4. Company overview – Merck & Co.
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.4(A) Executive profile  Merck & Co.
5.5. Company overview – Novartis
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.5(A) Executive profile  Novartis
5.6. Company overview – Sanofi Pasteur
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.6(A) Executive profile  Sanofi Pasteur
5.7. Company overview – CSL Limited
  Company snapshot
  Product offerings
  Growth strategies
  Initiatives
  Geographical presence
5.7(A) Executive profile  CSL Limited
Appendix
  List of tables
  Assumptions
  Conclusion
  Research methodology
  About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research